Compare Apartment Investment and Management Co (AIV) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apartment Investment and Management Co vs Novartis AG — how do they compare? Apartment Investment and Management Co trades at $2.62 (market cap $376.16M), while Novartis AG trades at $152.77 (market cap $295.37B). The key difference: Novartis AG is far larger — about 785.2× Apartment Investment and Management Co's market cap, and Novartis AG pays a 3.07% dividend while Apartment Investment and Management Co pays none. Which is the better fit depends on your goals.
| AIV | NVS | |
|---|---|---|
Market Cap | $376.16M | $295.37B |
Sector | Real Estate | Health |
52-Week High | $7.93 | $168.62 |
52-Week Low | $2.59 | $119.31 |
Enterprise Value | $738.32M | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.605, down 0.57% today, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q1 and Q4 2025 but missing in Q2 and Q3. Despite a net income margin of 400.05% in 2025, revenue declined to $138.49M from $209M in 2024. Analyst consensus shows 1 Buy and 2 Hold ratings, indicating cautious optimism. A dividend of $1.30 is scheduled for H1-2026.
Outlook: AIV's high profitability metrics and undervalued P/B ratio of 0.76 present potential upside, but declining revenue and bearish technicals pose risks. Investment opportunity lies in dividend yield and earnings recovery, while key risks include revenue volatility and competitive pressures in real estate.
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apartment Investment and Management Co
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
